Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — DnB Health Care Conference 2023
16 slides from Vitrolife Ab's conference presentation, Dec 14, 2023
Slide 1: Vitrolife Group – DnB Health Care Conference
Vitrolife Group DnB Health Care Conference 2023-12-14 Patrik Tolf CFO
Slide 2: Mission and key facts
Integrity Mission Be the leading global partner in reproductive health, Quality striving for better treatment outcomes for patients Global presence in Employees Sales in 2022 Innovation 125 markets ~ 1,100 3,234MSEK Collaboration 2
Slide 3: Vision: Enable people to fulfill the dream of having a healthy baby
Vision: Enable people to fulfill the dream of having a healthy baby Portfolio covering every step of the IVF journey combined with best-in-class quality, service and training IVF process Prenatal & Postnatal Pretreatment 3
Slide 4: Uniquely positioned to serve different standards of care
The Vitrolife Group is uniquely positioned to serve different standards of care Two methods for embryo evaluation m PGT- PGT-A Embrace M 1 Time-lapse technology-based assessment 2 Genetic assessment EmbryoScope® uses AI-based algorithms to analyse full course Analysis of embryo DNA to determine exis
Slide 5: Significant market opportunity in reproductive health
Significant market opportunity in reproductive health Successful treatment outcomes ~33% *** 1 in 6 134 M Access and affordability 5-7% people globally is babies born annually** estimated cycle affected by infertility* < 1% via IVF growth 5 *Source: World Health Organization **Source: United Nations
Slide 6: Improvement in treatment outcomes is needed
Improvement in treatment outcomes is needed Less than half of all embryos transferred today, result in pregnancy IVF birth rates have risen for patients under 43 in the last 30 years Birth rates per embryo transferred using patient eggs by age band, 1991-2018, 2019 data 35% Under 35 30% 25% 35-37 Bi
Slide 7: Our view: live birth rates
Our view 65 LIVE BIRTH RATES % 60 Endometrial 15% 55 50 Factor 45 40 Chromosomal 15% 35 Embryo Factor 30 25 20 15 10 IVF 1.0 IVF 2.0 5 1978 2010 7
Slide 8: Global access and affordability to IVF treatment is improving
Global access and affordability to IVF treatment is improving Country 2022 IVF treatments % of total China 1,045 25% Japan 511 12% USA 387 9% India 176 4% Russia 149 4% Spain 143 3% Other countries 1,746 42% Global 4,157 100% State fertility Insurance Coverage Laws; Twenty-one states have fertility
Slide 9: Key IVF market dynamics
Key IVF market dynamics – How can we bring value to the ecosystem Growth in demand Increase IVF capacity and accessibility Clinics labour and skills shortage Automation and digitalisation Consolidation of clinics Standardisation and scalability Diverse portfolio to address differences in Regionalisa
Slide 10: Committed to deliver sustainable profitable growth
Vitrolife Group committed to deliver sustainable profitable growth Focus on five strategic priorities 1. 2. 3. 4. 5. Own the Innovate to Accelerate Optimise go- Drive platform expand growth in key to-market operational connecting leadership markets model excellence products and services 10 Ensure su
Slide 11: It is all about data
It is all about data 5,000,000 embryo images/day 11
Slide 12: Continuing to advance our genetics portfolio
Continuing to advance our genetics portfolio to improve IVF outcomes IVF cycle pathway Stage of reproductive journey R&D priorities THE THE PA TIENTS ENDOM ETRIUM THE EM BRYO THE PREGNA NCY • WES • Future PGT-A R&D • New ERA • EMBRACE 2.0 • NIPT • WGS programmes • Ni Microbiota • niPOC analysis • In
Slide 13: Holistic embryo evaluation
Holistic embryo evaluation THE EMBRYO Comprehensive embryo evaluation combining EmbryoScope® and EMBRACE Prospective clinical study >200 patients >800 embryos 8 clinics 13
Slide 14: Corporate Strategy Vitrolife Group
Corporate Strategy Vitrolife Group Our values Integrity Market Growth Labour and Patient megatrends in demand skills shortage Consolidation Regionalisation empowerment Quality Vision with a purpose Long-term growth and profit objectives ”Enable people to fulfil the dream of having a healthy baby” In
Slide 15: Q&A
Q&A
Slide 16: Disclaimer
DISCLAIMER This presentation contains estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there i